Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine - LARVOL DELTA

Paced immune activation by AS04 drives superior cross-protective antibody response in Cervarix (IMMUNOLOGY 2025) - "Description The Gardasil®-4 vaccine targets HPV type 6,11,16 and 18 and is formulated with AlHO9PS-3. This results in delayed activation and sustained proliferation of adaptive immune cells at day 7, relying more on memory T and B cells. A paced immune activation may enhance adaptive immune cell maturation, providing a mechanism for improved cross-reactivity.Keywords: Animals Human; Cells B Cells Dendritic Cells T Cells; Processes Antigen Presentation/Processing"

BCL2 • CD4 • CDK1 • TLR4

Paced immune activation by AS04 drives superior cross-protective antibody response in Cervarix (ESCMID Global 2025) - No abstract available

HIV-Specific T & Humoral Response: Data From the First Pediatric Combined Therapeutic Vaccine Trial (CROI 2025) - "This study characterizes HIV-specific T and humoral responses following prime-boost vaccination of the HVRRICANE trial: HIVIS DNA and MVA-CMDR vaccines ± the TLR4 agonist with Cervarix HPV vaccine co-administration...No variation in single copy viral load was detected among and within Arms. Conclusions Data show strong and lasting HIV-specific immunity from the vaccine regimens tested, paving the way for immunotherapy to reduce the viral reservoir in children and youths with HIV."

Clinical • Human Immunodeficiency Virus • Infectious Disease • Pediatrics • IFNG • IL2 • TLR4

Therapeutic HIV Vaccine ± TLR4 Adjuvant Impact on Monocyte Subsets in Early-Treated Youths With HIV (CROI 2025) - "Additionally, in the ITM subset, Arm 2 exhibited a substantial (p= 0.028) increase in CD11b gMFI, peaking at wk 48; while Arm 1 demonstrated a significant (p=0.009) decrease in CD11c gMFI above the on ITM MO over time. Conclusions We observed distinct MO subset distribution and integrin/receptor expression following DNA prime and MVA boost vaccination regimens with Cervarix® co-administration."

Clinical • Human Immunodeficiency Virus • Infectious Disease • Pediatrics • CCR2 • CD33 • CD86 • CD93 • ITGA4 • ITGAM • ITGAX • TLR4

Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded. (PubMed, Infect Agent Cancer) - "Current HPV vaccines, including Cervarix®, Gardasil®, Gardasil®9, Cecolin®, and Walrinvax® utilize VLP (virus-like particle) structures and have demonstrated significant efficacy. Clinical trials are briefly reviewed, and potential strategies to advance vaccination against HPV-induced cervical cancer are summarized. This review emphasizes approaches that require further investigation in the future."

Journal • Review • Cervical Cancer • Oncology • Solid Tumor

Human Papillomavirus Vaccination in Saudi Arabia: A Narrative Review of Current Evidence. (PubMed, J Pharm Bioallied Sci) - "Despite the availability of effective vaccines such as Gardasil 9, Gardasil, and Cervarix, proper awareness and vaccination rates remain low in Saudi Arabia. International collaboration, such as initiatives by the Gavi alliance and sustained research efforts, is critical to optimizing HPV vaccine efficacy, accessibility, and uptake. Through coordinated efforts, the global burden of HPV-related diseases can be significantly reduced, ultimately leading to improved public health outcomes."

Journal • Review • Cervical Cancer • Infectious Disease • Oncology • Solid Tumor

Investigating factors affecting the effectiveness of Gardasil 4, Cervarix, and Gardasil 9 vaccines considering the WHO regions in females: A systematic review. (PubMed, Cancer Epidemiol) - "Various factors, including age, sex, common genotypes in population, culture, age at sexual initiation, healthcare system, and screening at recommended time, can play a significant role in vaccine effectiveness. Additionally, it is suggested that in the developing countries, a single dose vaccination program is sufficient for children aged 15 years or younger. Also in these countries, improving the care system, screening system, and awareness play a significant role in enhancing the effectiveness of vaccination. It is also recommended that studies on the effectiveness of the papilloma vaccination in the EMR and SEAR regions covered by the WHO to be conducted. According to the inclusion criteria, all countries were included in the study; thus, the effects of the individual's genotype, which depends on the geographical region, can affect the vaccine effectiveness. Individuals aged 9-45 who can receive the vaccine according to the guidelines, were included in the study...."

Journal • Review • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor

Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trial. (PubMed, Lancet Glob Health) - "A single dose of HPV vaccine in girls aged 9-14 years continues to provide stable immune responses 5 years after vaccination, although ongoing surveillance for potential waning immunity after a single dose is needed. Participants are being followed up to 9 years after vaccination."

Clinical • Journal • Human Papillomavirus Infection • Infectious Disease • Oncology

GSK's Cervarix won the HPV tender - huge discount made the difference [Google translation] (HealthTalk) - "After months of intense media pressure surrounding the HPV vaccine tender, the result is now clear: GSK's HPV vaccine Cervarix wins the tender ahead of MSD's Gardasil 9...The two vaccines that participated in the tender both protect well against HPV-related cancer and pre-cancerous conditions. The difference between the two is how broadly they protect: Cervarix protects against two types of HPV virus, while Gardasil 9 protects against nine types. This ensures, among other things, additional protection against genital warts....'Although Gardasil9 is more expensive per dose than Cervarix, the broader protection will provide savings in the long run. If you include indirect costs such as loss of productivity and other socio-economic burdens, the amounts are significantly higher.'"

Reimbursement • Anal Carcinoma • Cervical Cancer • Infectious Disease • Oropharyngeal Cancer

IMPACT OF AGE AT VACCINATION AND SEXUAL ACTIVITY ON HPV VACCINE IMMUNOGENICITY AT 5 YEARS AFTER A SINGLE DOSE IN THE DORIS TRIAL IN TANZANIA (IPVC 2024) - "The impact of age at vaccination and initiation of sexual activity on the durability of immune responses in young girls is important for policy makers. In the DoRIS trial, 930 Tanzanian girls aged 9-14y were randomised to receive 1, 2 or 3 doses of Gardasil-9® or Cervarix® (155 per arm). In girls in the primary target age range for HPV vaccination, there was some evidence of an impact of age and menarche status at vaccination on single-dose antibody responses, but this impact had reduced by M60. Higher antibody GMCs in sexually active participants suggest possible boosting of vaccine responses through sexual exposure to HPV."

DURABILITY OF ANTIBODY RESPONSES AGAINST VACCINE AND NON-VACCINE TYPES 3-4, 8-9 AND 13-14 YEARS AFTER EACH PROGRAMMATIC CHANGE OF THE HPV VACCINATION PROGRAMME IN ENGLAND (IPVC 2024) - "Initially, three doses of the bivalent (Cervarix®) vaccine were offered, which was replaced by the quadrivalent (Gardasil®) vaccine in 2012 and reduced to a two-dose schedule from 2014...The nonavalent (Gardasil®9) vaccine was introduced in 2022 which was reduced to a 1 dose regimen from 2023... Initial data from the serosurveillance show durability of high vaccine-induced antibody levels in vaccinated girls into adulthood. In time, as additional age-specific cohorts are included, this surveillance will be able to compare antibody levels between the girls' and boys' programmes, the bivalent, quadrivalent and nonavalent vaccines and different dosing regimens. This serosurveillance will aim to identify any reductions in vaccine-induced antibodies that could foretell of a potential weakening in HPV control."

Prevalence, Characteristics, and Distribution of Human Papillomavirus According to Age and HIV Status in Women of Eastern Cape Province, South Africa. (PubMed, Viruses) - "A proportion of 12.9% were infected with one or more HPV types covered by the Cervarix® HPV vaccine (HPV-16 and/or -18), 18.8% (by those covered by Gardasil®4 (HPV-6, -11, -16 and/or -18), and 42.2% by those covered by Gardasil®9 (HPV-6, -11, -16, -18, -31, -33, -45, -52 and/or -58). High overall HPV, HR-HPV, and alpha-9 species prevalence were observed among the women attending the public health facility. These findings contribute to the limited HPV distribution data among the Eastern Cape women, which could be used to improve HPV-related policy and assess the effectiveness of the HPV vaccination."

Journal • Cervical Cancer • Human Immunodeficiency Virus • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor

THE CHANGE IN PREVALENCE OF HIGH-RISK HPV GENOTYPES IN CERVICAL CANCER AND PRECANCER IN LATVIA FROM 2016 TO 2024. (IPVC 2024) - "HPV vaccination in Latvia started in 2010 with Cervarix, replaced by Gardasil9 in 2020. HPV16 is the most prevalent among HPV-nonvaccinated. HPV16/18, which have been targeted by vaccines the longest, are decreasing in prevalence, while others are on the rise. HPV16/18 decrease might signify a herd effect and have opened a niche for other hrHPVs."

Cervical Cancer • Gynecology • Oncology • Solid Tumor

The HPV decision is postponed by four weeks [Google translation] (HealthTalk) - "The channel reports that the postponement has been announced in Mercell, which is a monitoring service for tender processes...The specialist group has given feedback that they need more time to evaluate received offers for the HPV vaccine, and we will therefore publish the award within week 50, says Sykehusinnjøk in the announcement...Originally, the award was to be published this week. The vaccine offered today is Cervarix and protects against two HPV variants, HPV 16 and 18. They account for around 70 percent of all cases of cervical cancer...Gardasil 9 is the alternative, and it protects against nine HPV variants and against genital warts...The Norwegian Cancer Society, a number of politicians and experts would rather have the newer vaccine Gardasil 9, even though it costs much more to purchase....A dose of Cervarix costs NOK 926, according to Apotek1. Gardasil 9 costs NOK 1,619."

Reimbursement • Cervical Cancer • Gynecologic Cancers • Oncology • Solid Tumor

PRECLINIC IMMUNOGENICITY STUDY OF A RECOMBINANT HUMAN PAPILLOMAVIRUS NONAVALENT VIRUS-LIKE PARTICLE VACCINE (IPVC 2024) - "Currently, six prophylactic HPV vaccines are available on the market: Cervarix, Gardasil and Gardasil 9, Cervavac and Cecolin and Walrinvax. These immunogenicity data in different animal species demonstrated that the HPV-9 candidate vaccine might provide a comparable protection against HPV infection to those of Gardasil 9, which support further investigation of the efficacy of the vaccine in clinical trials."

Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study (clinicaltrials.gov) - P4 | N=28000 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor

HPV VACCINE EFFECTIVENESS AGAINST ANAL HPV-16 AND HPV-18 INFECTIONS AMONG YOUNG MEN WHO HAVE SEX WITH MEN (HPV4M): STUDY PROTOCOL OF AN OBSERVATIONAL STUDY (IPVC 2024) - "Introduction: In the Netherlands, all adolescents aged 19-26 years were offered prophylactic immunization with the bivalent HPV-16/18 vaccine (Cervarix®) as part of the national catch-up campaign (January-June 2023)... Assessing HPV vaccine effectiveness in a routine public health setting is critical to judge whether HPV vaccination of young adult MSM is an effective intervention."

Clinical • Observational data • Anal Carcinoma • Infectious Disease • Oncology • Solid Tumor

FINAL RESULTS FROM A NON-RANDOMIZED, OPEN-LABEL IMMUNOBRIDGING TRIAL COMPARING HPV16/18-ANTIBODIES IN GIRLS WHO RECEIVED ONE DOSE CERVARIX® TO WOMEN WHO RECEIVED THREE DOSES GARDASIL®: PRIMAVERA (IPVC 2024) - No abstract available

Clinical • Late-breaking abstract

Has announced a tender for the HPV vaccine [Google translation] (MedWatch) - "The estimated value of the tender is NOK 692 million (excl. VAT), according to the tender basis that has now been published...It is Cervarix that is used in today's vaccination programme...The HPV vaccine is part of the childhood vaccination programme, and the aim is to prevent cervical cancer, as well as other forms of cancer in both sexes caused by HPV....The procurement is carried out by Sykehusinkjøp on behalf of the Directorate for Medical Products (DMP). The Norwegian Institute of Public Health previously had this responsibility, but this year Sykehusinnkjøp took over the responsibility."

Commercial • Cervical Cancer • Gynecologic Cancers • Oncology • Solid Tumor

Effectiveness of HPV vaccine as part of national immunization program for preventing HPV infection in Thai schoolgirls after seven years post-vaccination. (PubMed, Hum Vaccin Immunother) - "Between May and June 2023, 211 grade 12 female students from Ayutthaya, who received the two-dose bivalent HPV vaccine CERVARIXⓇ (HPV types 16 and 18), and 376 grade 12 students from Nakhon Pathom who did not receive the HPV vaccine, were enrolled...Our findings indicated that the bivalent HPV vaccine does not provide cross-protection against non-vaccine HPV types. Prioritizing vaccines with the highest coverage of HR-HPV types, such as the nonavalent HPV vaccine, is crucial to effectively prevent a broader range of HR-HPV infections under the NIP."

Journal • Human Papillomavirus Infection • Infectious Disease

Update on Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology. (PubMed, Viruses) - "Most national prophylactic HPV vaccination programs started in approximately 2008, with either the bivalent Cervarix HPV16/18 or quadrivalent Gardasil (HPV6/11/16/18) vaccines, which were then followed by introduction of the nonavalent Gardasil 9 (HPV6/11/16/18/ 31/33/45/52/58) vaccine from 2015. In conclusion, it is not yet clear what effect dissemination of vaccine-associated changes in HPV type prevalence will have on vaccine efficacy and cervical pathology, particularly in mixed populations of vaccinated and unvaccinated women. However, it is very clear these observations do underscore the need for long-term continuation of cervical screening combined with regular reassessment of testing practices."

Journal • Review • Cervical Cancer • Gynecology • Infectious Disease • Oncology • Solid Tumor

How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects? (PubMed, Vaccine) - "Surveillance of type-specific infections in vaccine-eligible populations in England has generated clear evidence of cross-protective effects from HPV16/18-AS04 vaccination against high-risk HPV 31/33/45 infections, consistent with other post-implementation observations and confirming and in some ways exceeding expectations from clinical trials."

Journal • Infectious Disease • Oncology

From September, greater access to HPV vaccinations. What will change? Lubuskie NFZ responds [Google translation] (Gazeta Lubuska) - "As announced by the Ministry of Health, starting in September of this year, the HPV vaccination program will cover children from the age of 9 to the age of 14. The rules for implementing the program for healthcare providers will also be simplified. These changes are intended to improve the effectiveness of the program...June this year marked a year since the launch of the free HPV vaccination program for children aged 12-13. In the Lubuskie province, over 7,000 children have been vaccinated so far - informs Joanna Branicka, spokeswoman for the Lubuskie branch of the National Health Fund...Two HPV vaccines are available under the program: the 2-valent Cervarix vaccine and the 9-valent Gardasil 9 vaccine....Additionally, the Cervarix vaccine is available free of charge as part of a refund to persons aged 9 to 18 years and as part of a 50% refund to adults."

Reimbursement • Anal Carcinoma • Cervical Cancer • Gynecologic Cancers • Oncology • Oropharyngeal Cancer • Solid Tumor • Vaginal Cancer

HPV vaccinations for children as young as nine [Google translation] (Prawo.pl) - "The Ministry of Health has expanded the age group covered by the free HPV vaccination program. From September 1, 2024, children will be able to receive it not from the age of 11, as is currently the case, but from the age of 9 to 14. The Ministry of Health has issued a statement on this matter. The rule that HPV vaccination is listed as recommended, not mandatory, remains unchanged. It is therefore up to the parents whether the child receives the preparation....The vaccine is administered in a two-dose regimen. The preparation is administered as an intramuscular injection into the deltoid muscle. Two HPV vaccines are available free of charge under the program: the bivalent Cervarix vaccine and the 9-valent Gardasil 9 vaccine."

Reimbursement • Anal Carcinoma • Cervical Cancer • Gynecologic Cancers • Oncology • Penile Cancer • Solid Tumor • Vulvar Cancer

Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial (clinicaltrials.gov) - P3 | N=1240 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed

Head-to-Head • Trial completion • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor